Clinical assessment of spasticity in children with cerebral palsy: a critical review of available instruments

This study reviews the instruments used for the clinical assessment of spasticity in children with cerebral palsy, and evaluates their compliance with the concept of spasticity, defined as a velocity‐dependent increase in muscle tone to passive stretch. Searches were performed in Medline, Embase, and Cinahl, including the keywords ‘spasticity’, ‘child’, and‘cerebral palsy’, to identify articles in which a clinical method to measure spasticity was reported. Thirteen clinical spasticity assessment instruments were identified and evaluated using predetermined criteria. This review consists of reports on the standardization applied for assessment at different velocities, testing posture, and quantification of spasticity. Results show that most instruments do not comply with the concept of spasticity; standardization of assessment method is often lacking, and scoring systems of most instruments are ambiguous. Only the Tardieu Scale complies with the concept of spasticity, but this instrument has a comprehensive and time–consuming clinical scoring system.

[1]  P. Steinbok.  Outcomes after selective dorsal rhizotomy for spastic cerebral palsy , 2001, Child's Nervous System.

[2]  C. Bérard,et al.  ÉVALUATION CLINIQUE DE L'ENFANT SPASTIQUE , 2003 .

[3]  A. Gordon,et al.  Relation between clinical measures and fine manipulative control in children with hemiplegic cerebral palsy , 1999, Developmental medicine and child neurology.

[4]  W. Poewe,et al.  Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: an open‐label study in 10 children with equinus gait pattern , 1999 .

[5]  F. Heinen,et al.  Evaluation of Botulinum Toxin A Therapy in Children With Adductor Spasm by Gross Motor Function Measure , 2000, Journal of child neurology.

[6]  F. Grotenhermen.  Einige praxisrelevante Aspekte der Pharmakokinetik von THC , 1999, Complementary Medicine Research.

[7]  D. Cochrane,et al.  Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. , 1997, Journal of neurosurgery.

[8]  W. Peacock,et al.  Cerebral palsy spasticity. Selective posterior rhizotomy. , 1987, Pediatric neuroscience.

[9]  J. Brennan.  Clinical Method of Assessing Tonus and Voluntary Movement in Hemiplegia* , 1959, British medical journal.

[10]  W. Poewe,et al.  Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment. , 1999, Neuropediatrics.

[11]  S. Wientroub,et al.  Parameters for Predicting Favorable Responses to Botulinum Toxin in Children With Cerebral Palsy , 2002, Journal of child neurology.

[12]  T. Carey.  Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy, , 2003, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[13]  J. Loeser,et al.  Long‐term safety and efficacy of continuous intrathecal baclofen , 2002, Developmental medicine and child neurology.

[14]  R. Boyd,et al.  Medium‐term response characterisation and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy , 1999 .

[15]  Richard W. Bohannon,et al.  Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.

[16]  Subramanian,et al.  Selective dorsal rhizotomy as a treatment option for children with spastic cerebral palsy. , 1998, Gait & posture.

[17]  F. Heinen,et al.  Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: the parents' view of functional outcome , 1999 .

[18]  V. Lacroix,et al.  Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: a pilot project. , 1999, Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc.

[19]  H. Cohen,et al.  Residual spasticity after selective posterior rhizotomy , 1995, Child's Nervous System.

[20]  R. Penn,et al.  Multidimensional assessment of motor function in a child with cerebral palsy following intrathecal administration of baclofen. , 1997, Physical therapy.

[21]  N. Young,et al.  Windswept Hip Deformity in Spastic Quadriplegic Cerebral Palsy , 1998 .

[22]  J. Bodensteiner,et al.  Treatment of spastic gait in cerebral palsy. , 1994, West Virginia Medical Journal.

[23]  Threshold electrical stimulation (TES) in ambulant children with CP: a randomized double‐blind placebo‐controlled clinical trial , 2002, Developmental medicine and child neurology.

[24]  F. Lang,et al.  Inclusion of the S2 dorsal rootlets in functional posterior rhizotomy for spasticity in children with cerebral palsy. , 1994, Neurosurgery.

[25]  L. Staudt,et al.  Spasticity in Cerebral Palsy and the Selective Posterior Rhizotomy Procedure , 1990, Journal of child neurology.

[26]  H. Waddy,et al.  Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy , 1999, Journal of paediatrics and child health.

[27]  R. Calderón-González,et al.  Botulinum toxin A in management of cerebral palsy. , 1994, Pediatric neurology.

[28]  'Electro-acupuncture in a child with mild spastic hemiplegic cerebral palsy'. , 2003, Developmental medicine and child neurology.

[29]  M. Galli,et al.  Short-term effects of "botulinum toxin a" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. , 2001, Functional neurology.

[30]  A. Castro-Caldas,et al.  Influence of learning to read and write on the morphology of the corpus callosum , 1999, European journal of neurology.

[31]  C. Buckon,et al.  Developmental skills of children with spastic diplegia: functional and qualitative changes after selective dorsal rhizotomy. , 1997, Archives of physical medicine and rehabilitation.

[32]  N. Stott,et al.  Intrarater reliability of lower limb sagittal range-of-motion measures in children with spastic diplegia. , 2003, Developmental medicine and child neurology.

[33]  S. Brown,et al.  Motor control testing of upper limb function after botulinum toxin injection: a case study. , 2000, Archives of physical medicine and rehabilitation.

[34]  Brennan Jb.  Response to stretch of hypertonic muscle groups in hemiplegia. , 1959 .

[35]  K. Salame,et al.  Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. , 2003, The Israel Medical Association journal : IMAJ.

[36]  G. Molenaers,et al.  Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. , 2000, Gait & posture.

[37]  J. Janosky,et al.  Continuous intrathecal baclofen infusion for spasticity of cerebral origin. , 1993, JAMA.

[38]  Eva Nordmark,et al.  Wartenberg pendulum test: objective quantification of muscle tone in children with spastic diplegia undergoing selective dorsal rhizotomy , 2002, Developmental medicine and child neurology.

[39]  B Hagberg,et al.  Changing panorama of cerebral palsy in Sweden. VIII. Prevalence and origin in the birth year period 1991–94 , 2001, Acta paediatrica.

[40]  J Denoth,et al.  The importance of posture on the isokinetic assessment of spasticity , 2002, Spinal Cord.

[41]  R. Chan,et al.  Effect of Botulinum Toxin Type A on Cerebral Palsy with Upper Limb Spasticity , 2003, American journal of physical medicine & rehabilitation.

[42]  W. Rymer,et al.  Spastic hypertonia: mechanisms and measurement. , 1989, Archives of physical medicine and rehabilitation.

[43]  C. A. Trombly,et al.  Occupational Therapy for Physical Dysfunction , 1989 .

[44]  W. Lajara-Nanson,et al.  Use of Modafinil in Spastic Cerebral Palsy , 2002, Journal of child neurology.

[45]  C. Price,et al.  The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia a randomized controlled trial , 2001, European journal of neurology.

[46]  C. Detrembleur,et al.  Botulinum toxin and short‐term electrical stimulation in the treatment of equinus in cerebral palsy , 2002, Movement disorders : official journal of the Movement Disorder Society.

[47]  R. Price,et al.  Electrophysiological monitoring during selective dorsal rhizotomy, and spasticity and GMFM performance , 1998, Developmental medicine and child neurology.

[48]  G. Serdaroğlu,et al.  The use of botulinum toxin type A treatment in children with spasticity. , 2003, Pediatric neurology.

[49]  AD Pandyan,et al.  Spasticity: Clinical perceptions, neurological realities and meaningful measurement , 2005, Disability and rehabilitation.

[50]  F. Heinen,et al.  Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. , 1997, Pediatric rehabilitation.

[51]  M. Hallett,et al.  Classification and definition of disorders causing hypertonia in childhood. , 2003, Pediatrics.

[52]  A. L. Albright.  Topical Review: Baclofen in the Treatment of Cerebral Palsy , 1996 .

[53]  L. Mutch,et al.  Cerebral Palsy Epidemiology: Where are We Now and Where are We Going? , 1992, Developmental medicine and child neurology.

[54]  M. Levin,et al.  Regulation of stretch reflex threshold in elbow flexors in children with cerebral palsy: a new measure of spasticity , 2000, Developmental medicine and child neurology.

[55]  S. Õunpuu,et al.  Effects of selective dorsal rhizotomy on gait in children with cerebral palsy. , 1993, Journal of pediatric orthopedics.

[56]  T. Chuang,et al.  Treatment of cerebral palsy with botulinum toxin: evaluation with gross motor function measure. , 1999, Journal of the Formosan Medical Association = Taiwan yi zhi.

[57]  C. Tylkowski,et al.  Nonselective Partial Dorsal Rhizotomy: A Clinical Experience with 1-Year Follow-Up , 2000, Pediatric Neurosurgery.

[58]  M. Johnston,et al.  Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. , 2000, American journal of physical medicine & rehabilitation.

[59]  K. Granata,et al.  Spastic velocity threshold constrains functional performance in cerebral palsy. , 2003, Archives of physical medicine and rehabilitation.

[60]  W. Peacock,et al.  Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. , 1991, Journal of neurosurgery.

[61]  S. Seri,et al.  The Effect of Intrathecal Baclofen on Muscle Co-Contraction in Children with Spasticity of Cerebral Origin , 2002, Pediatric Neurosurgery.

[62]  J. Perry.  Determinants of Muscle Function in the Spastic Lower Extremity , 1993, Clinical orthopaedics and related research.

[63]  S. Naumann,et al.  Evaluation of selective dorsal rhizotomy for the reduction of spasticity in cerebral palsy: a randomized controlled trial , 1998, Developmental medicine and child neurology.

[64]  H. Dumas,et al.  Impairment, Disability, and Satisfaction Outcomes After Lower‐Extremity Botulinum Toxin A Injections for Children with Cerebral Palsy , 2002, Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.

[65]  S. Walt,et al.  Intraobserver reliability of the modified Tardieu scale in the upper limb of children with hemiplegia , 2004, Developmental medicine and child neurology.

[66]  A. Thévenon,et al.  Spasticité et distribution des pressions plantaires chez des enfants atteints d'hémiplégie cérébrale infantile , 2001 .

[67]  A. Scheinberg,et al.  Continuous intrathecal baclofen infusion for children with cerebral palsy: A pilot study , 2001, Journal of paediatrics and child health.

[68]  N. Haney.  Muscle Strengthening in Children with Cerebral Palsy , 1998 .

[69]  B Hagberg,et al.  The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth‐year period 1995–1998 , 1996, Acta paediatrica.

[70]  J. Farmer,et al.  Long-term functional outcome after selective posterior rhizotomy. , 2002, Journal of neurosurgery.

[71]  T. Wurdinger,et al.  Implanted pump systems for treatment of spasticity. , 1988, Acta neurochirurgica. Supplementum.

[72]  D. Fehlings,et al.  Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome , 2001, European Journal of Neurology.

[73]  Efficacy for Maintenance of Elbow Range of Motion of Two Types of Orthotic Devices: A Case Series , 2003 .

[74]  Neurological mechanisms in spasticity: a brief review of some current concepts. , 1976, Physiotherapy.

[75]  A. L. Albright,et al.  Intrathecal baclofen for spasticity in cerebral palsy. , 1991, JAMA.

[76]  J. Janosky,et al.  Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. , 1995, Pediatric neurosurgery.

[77]  A. Michon,et al.  Functional Assessment Following Intrathecal Baclofen Therapy in Children With Spastic Cerebral Palsy , 2003, Journal of child neurology.

[78]  S. Hesse,et al.  Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. , 2000, Restorative neurology and neuroscience.

[79]  R. Price,et al.  Selective dorsal rhizotomy: efficacy and safety in an investigator‐masked randomized clinical trial , 1998, Developmental medicine and child neurology.

[80]  L. von Wendt,et al.  Follow-up of children with cerebral palsy after selective posterior rhizotomy with intensive physiotherapy or physiotherapy alone. , 2003, Neuropediatrics.

[81]  H Forssberg,et al.  Quantitative assessment of mirror movements in children and adolescents with hemiplegic cerebral palsy , 2000, Developmental medicine and child neurology.

[82]  I. Najm,et al.  Nerve rootlets to be sectioned for spasticity resolution in selective dorsal rhizotomy. , 2000, Surgical neurology.

[83]  S. Astley,et al.  THE ROLE OF SELECTIVE DORSAL RHIZOTOMY IN cérébral PALSY: CRITICAL EVALUATION OF A PROSPECTIVE CLINICAL SERIES , 1994, Developmental medicine and child neurology.

[84]  K. Arimura,et al.  Reversible F‐wave hyperexcitability associated with antibodies to potassium channels in Isaacs' syndrome , 1999, European journal of neurology.

[85]  R. Beauchamp,et al.  A randomized clinical trial to compare selective posterior rhizotomy plus physiotherapy with physiotherapy alone in children with spastic diplegic cerebral palsy , 1997, Developmental medicine and child neurology.

[86]  T. Sandell,et al.  Botulinum toxin for spasticity and athetosis in children with cerebral palsy. , 1996, Archives of physical medicine and rehabilitation.

[87]  Chang-il Park,et al.  Selective posterior rhizotomy in children with cerebral palsy: a 10-year experience , 2001, Child’s Nervous System.

[88]  J. Sławek,et al.  Functional improvement in cerebral palsy patients treated with botulinum toxin A injections – preliminary results , 2003, European journal of neurology.

[89]  R. Penn,et al.  Intrathecal baclofen for motor disorders , 1995, Movement disorders : official journal of the Movement Disorder Society.

[90]  D. Quartermain,et al.  Selective dorsal rhizotomy: outcome and complications in treating spastic cerebral palsy. , 1993, Neurosurgery.

[91]  A. L. Albright.  Baclofen in the treatment of cerebral palsy. , 1996, Journal of child neurology.

[92]  L. Lagae,et al.  Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. , 2000, Neurosurgery.

[93]  W Z Rymer,et al.  A simulation study of reflex instability in spasticity: origins of clonus. , 1999, IEEE transactions on rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society.

[94]  T N Theologis,et al.  Collagen accumulation in muscles of children with cerebral palsy and correlation with severity of spasticity. , 2001, Developmental medicine and child neurology.

[95]  I. Hwang,et al.  Quantitative analysis of the velocity related pathophysiology of spasticity and rigidity in the elbow flexors , 2002, Journal of neurology, neurosurgery, and psychiatry.

[96]  B. Ashworth.  PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS. , 1964, The Practitioner.

[97]  H. Wiens,et al.  Spasticity in children with cerebral palsy: a retrospective review of the effects of intrathecal baclofen. , 1998, Issues in comprehensive pediatric nursing.

[98]  Chang-il Park,et al.  Selective posterior rhizotomy for lower extremity spasticity: how much and which of the posterior rootlets should be cut? , 2002, Surgical neurology.

[99]  S. Pradhan,et al.  "Extensor Toe Sign" by Various Methods in Spastic Children With Cerebral Palsy , 1998, Journal of child neurology.

[100]  V. Wong,et al.  Use of botulinum toxin injection in 17 children with spastic cerebral palsy. , 1998, Pediatric neurology.

[101]  Physical Management of Spasticity , 2001, Journal of child neurology.

[102]  A. Livanelioğlu,et al.  Effects of Johnstone pressure splints combined with neurodevelopmental therapy on spasticity and cutaneous sensory inputs in spastic cerebral palsy. , 2001, Developmental medicine and child neurology.

[103]  A. Ward.  The use of botulinum toxin type A in spastic diplegia due to cerebral palsy , 1999 .

[104]  E. Fowler,et al.  Sensitivity of the pendulum test for assessing spasticity in persons with cerebral palsy , 2000, Developmental medicine and child neurology.

[105]  M. Abel,et al.  Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function , 2001, European journal of neurology.

[106]  K. Moore,et al.  Orthopedic procedures after rhizotomy. , 1998, Journal of pediatric orthopedics.

[107]  E. Mattsson,et al.  Oxygen cost, walking speed, and perceived exertion in children with cerebral palsy when walking with anterior and posterior walkers , 1997, Developmental medicine and child neurology.

[108]  L. Krach,et al.  Intrathecal Baclofen for Management of Spastic Cerebral Palsy: Multicenter Trial , 2000, Journal of child neurology.

[109]  P. Filipetti,et al.  [Interest of anesthetic blocks for assessment of the spastic patient. A series of 815 motor blocks]. , 2003, Neuro-Chirurgie.

[110]  J. Nunemacher,et al.  Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.

[111]  M. Sindou,et al.  Microsurgical DREZ-otomy for the treatment of spasticity and pain in the lower limbs. , 1989, Neurosurgery.

[112]  A. Cosgrove,et al.  Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. , 1998, Journal of pediatric orthopedics.

[113]  J Harlaar,et al.  Measurement of impaired muscle function of the gastrocnemius, soleus, and tibialis anterior muscles in spastic hemiplegia: a preliminary study. , 1998, Journal of rehabilitation research and development.

[114]  P. Steinbok,et al.  Long-Term Outcome after Selective Posterior Rhizotomy in Children with Spastic Cerebral Palsy , 1999, Pediatric Neurosurgery.

[115]  Chang-il Park,et al.  The effect of spasticity on cortical somatosensory-evoked potentials: changes of cortical somatosensory-evoked potentials after botulinum toxin type A injection. , 2002, Archives of physical medicine and rehabilitation.

[116]  G R Johnson,et al.  Outcome measures of spasticity. , 2002, European journal of neurology.

[117]  M. Aiona,et al.  Gait changes in children with spastic diplegia after selective dorsal rhizotomy. , 1996, Journal of pediatric orthopedics.

[118]  G. Cioni,et al.  Use of botulinum toxin type A in walking disorders of children with cerebral palsy , 2001 .

[119]  N. Mayer,et al.  Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion , 1997, Muscle & nerve. Supplement.

[120]  P. Steinbok,et al.  Comparison of Motor Outcomes after Selective Dorsal Rhizotomy with and without Preoperative Intensified Physiotherapy in Children with Spastic Diplegic Cerebral Palsy , 2002, Pediatric Neurosurgery.

[121]  A. Purohit,et al.  Selective Musculocutaneous Fasciculotomy for Spastic Elbow in Cerebral Palsy: A Preliminary Study , 1998, Acta Neurochirurgica.

[122]  C. Arnaud,et al.  Toxine botulinique dans la spasticité des adducteurs de hanche chez les enfants IMC et IMOC non marchants , 2002 .

[123]  D. Sutherland,et al.  Relationships Among Musculoskeletal Impairments and Functional Health Status in Ambulatory Cerebral Palsy , 2003, Journal of pediatric orthopedics.

[124]  J. Lazareff,et al.  Limited (L4-S1, L5-S1) Selective Dorsal Rhizotomy for Reducing Spasticity in Cerebral Palsy , 1999, Acta Neurochirurgica.

[125]  E. Dursun,et al.  THE ROLE OF BOTULINUM TOXIN A IN THE MANAGEMENT OF LOWER LIMB SPASTICITY IN PATIENTS WITH CEREBRAL PALSY , 2002, International journal of clinical practice.

[126]  Gerry E Conti,et al.  Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. , 2003, Archives of physical medicine and rehabilitation.

[127]  Clinical utility of the Duncan-Ely test for rectus femoris dysfunction during the swing phase of gait. , 2003, Developmental medicine and child neurology.

[128]  D Fehlings,et al.  An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. , 2000, The Journal of pediatrics.

[129]  A. Suputtitada.  Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: preliminary report. , 2000, American journal of physical medicine & rehabilitation.

[130]  M. Galea,et al.  Measures of muscle and joint performance in the lower limb of children with cerebral palsy , 2003, Developmental medicine and child neurology.

[131]  J. Lazareff,et al.  Limited selective posterior rhizotomy for the treatment of spasticity secondary to infantile cerebral palsy: a preliminary report. , 1990, Neurosurgery.

[132]  E. Fowler,et al.  Functional Assessment of Children with Cerebral Palsy Following Limited (L4-S1) Selective Posterior Rhizotomy – A Preliminary Report , 2001, Acta Neurochirurgica.

[133]  N. Temkin,et al.  Selective dorsal rhizotomy: meta‐analysis of three randomized controlled trials , 2002, Developmental medicine and child neurology.

[134]  Diane L Damiano,et al.  What does the Ashworth scale really measure and are instrumented measures more valid and precise? , 2002, Developmental medicine and child neurology.

[135]  Roslyn N. Boyd,et al.  Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy , 1999 .

[136]  V. Wong,et al.  Open-Label Study of Botulinum Toxin for Upper Limb Spasticity in Cerebral Palsy , 2002, Journal of child neurology.

[137]  S. Kameyama,et al.  Functional posterior rhizotomy for severely disabled children with mixed type cerebral palsy. , 2003, Acta neurochirurgica. Supplement.

[138]  L. Paul,et al.  Demonstration of delayed recovery from fatiguing exercise in chronic fatigue syndrome , 1999, European journal of neurology.

[139]  M. J. Murphy.  New York University Rhizotomy Program: Physical Therapy Rhizotomy Evaluation , 1990 .

[140]  F. Heinen,et al.  Medium‐term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1‐year follow‐up using gross motor function measure , 2001, European journal of neurology.

[141]  C. Hoff,et al.  Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. , 2002, Archives of physical medicine and rehabilitation.

[142]  A P Cosgrove,et al.  Botulinum toxin A in hamstring spasticity. , 1999, Gait & posture.

[143]  Anatol G. Feldman,et al.  The role of stretch reflex threshold regulation in normal and impaired motor control , 1994, Brain Research.

[144]  M. Abel.  Orthopedic Management in Cerebral Palsy , 1989 .

[145]  M. Levin,et al.  Relief of hemiparetic spasticity by TENS is associated with improvement in reflex and voluntary motor functions. , 1992, Electroencephalography and clinical neurophysiology.